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This report describes the results ofa collaborative study organized
by a joint working group of the IFCC and WHO and involving
nine manufacturers of TSH immunometric assay kits. The study
was designed to determine whether a calibrator with a common
matrix gives better between-laboratory agreementfor calibration of
serum samples than the various kit calibrators, and to assess various
materials for their suitability for use as common matrices. Kit
calibrators, or calibrators consisting of the IRPfor TSH made up
in two common matrices: (a) serumfrom patients with untreated
thyrotoxicosis or (b) serum taken from subjects treated with
suppressive doses of triiodothyronine, gave similar results for the
between-laboratory variation ofestimates ofTSH concentrationfor
a range of serum samples. Dose-response curves for the two
calibrators in ’common’ matrices were similar to one another and to
thosefor the kit calibrator. However, the occurrence ofnon-specific
serum effects is shown by the comparison of results for these
calibrators with resultsfor calibrators made up in a third common
matrix: serum treated with wheat germ lectin. Dose response curves
for this calibrator were dissimilar to thosefor the other calibrators
and between-laboratory variation for estimates in terms of this
latter calibrator showed a substantial increase. Moreover, although
the between-laboratory variances for estimates of the TSH
concentration in terms of each of these calibrators (except those
made up in serum treated with the wheat germ lectin) were similar
for any one sample from five hyperthyroid patients, the variances
were not consistent between samples, evenfor samples with similar
mean TSH concentrations. These results suggest that a majorfactor
in the between-laboratory variation, especially in the region near
’zero dose’, is sample-related, and is caused by particular samples
interacting differently with different assay systems.
In general, it would appear that for the well-controlled ’ultra-
sensitive’ TSH immunometric assay kits, included in this study,
between-laboratory agreement of estimates of the TSH concen-
tration in serum samples is not likely to be substantially improved
by use of a common matrix for the standards.
IgG Immunoglobulin-G
WGL Wheat germ lectin
C.V. Coefficient of variation
Introduction
At the 36th meeting of WHO’s Expert Committee on
Biological Standardization, the need for matrix standards
to improve calibration of ligand assay kits for estimation
of hormones was considered (WHO, 1987), and it was
agreed that a joint working group ofIFCC andWHO be
set up to conduct a feasibility study into this matter. This
working group agreed that a collaborative study should
be undertaken to investigate whether calibration ofserum
samples, in terms of the IRP for TSH in a common
matrix, shows better between-laboratory agreement than
calibration in terms ofkit standards. The group discussed
various materials which may be suitable for use as a
common matrix and samples were obtained and ex-
amined in a collaborative study.
Aims of the study
The aim of the study was to assses four low TSH serum
preparations for their suitability for serving as a common
matrix for TSH assays: (a) from untreated thyrotoxic
patients; (b) from triiodothyronine-suppressed volun-
teers, in both frozen and lyophilized form; and (c) from
samples where the glycoproteins had been removed by
wheat germ lectin chromatography.
Materials for the study
(1) Matrices
Thyrotoxic serum: Some 200 serum samples, ranging in
volume from 2 to 40 ml, were obtained from untreated
patients with long-term thyrotoxicosis, each containing
less than 0"05 mU-L TSH by immunoassay, and no
detectable anti-mouse igG.
Abbreviations
TSH
IRP
T3
Thyroid stimulating hormone (thyrotropin)
International reference preparation
Triiodothyronine
T.-suppressed serum: Some 200 to 250 ml of serum was
collected from each of 22 healthy volunteers who had
taken suppresssive doses of triiodothyronine (80 bg per
day) for five days prior to serum donation, each sample
containing less than 0"05 mU/L TSH and no detectable
anti-mouse IgG.
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WGL serum: Serum from healthy volunteers was mixed
gently for 16 h with WGL-Sepharose-6MB (Pharmacia)
and collected by filtration, lyophilized and reconstituted
in water.
(2) TSH standards
The ampouled preparation 81/565 contains highly-
purified pituitary TSH identical to that used in the 2nd
International Reference Preparation (IRP), and is cali-
brated in terms of the 2nd IRP [1].
(3) Patient samples
Samples ranging from 25 to 50 ml were collected from
each of 11 patients who were either hypothyroid,
euthyroid or hyperthyroid, and these were filtered and
distributed into 0"5 ml portions.
Study design
The study was designed to calibrate a panel of clinical
serum samples using both in-houseTSH assay standards,
i.e. kit calibrators, or ’calibrator sets’ prepared in a
common matrix, and to compare the intra- and inter-
laboratory variability obtained by these calibrations.
Each assay that individual participants performed con-
tained the following standard curves:
(1) Individual kit-calibrator or in-house standard
curve.
(2 and 3) Standard curves in duplicate, prepared in
thyrotoxic serum by the organizers and distributed
frozen to participants.
(4 and 5) Standard curves in duplicate, prepared in
T3-suppressed serum by the organizers and dis-
tributed frozen to participants.
(6) Standard curve, prepared in WGL serum by the
organizers and distributed frozen to participants.
(7) Standard curve prepared in-house by each partici-
pant using T3-suppressed serum as diluent, dis-
tributed frozen to participants.
(8) Standard curve prepared in-house by participants
using freeze-dried Ta-suppressed serum as diluent,
supplied by the organizers.
(9) Standard curve prepared in-house by participants
using freeze-dried WGL serum as diluent, supplied by
the organizers.
The samples comprising curves (2)-(6) were provided
coded and in random order amongst the distributed
serum samples and were not distinguishable from the
’patient’ serum samples. In each assay, the TSH content
ofthe unknowns was estimated using each ofthe standard
curves.
Comparisons of the results obtained with curve (1) and
curves (2)-(9) would indicate any improvement in
comparability obtained by using a common standard
curve prepared in a common matrix. Comparisons of
results obtained from curves (2)-(6) with results from
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(7)-(9) would allow separation of that improvement into
components derived from the use ofa common matix, and
from the removal of in-house dilution errors. Assessment
of results obtained from curves (7), (8) and (9) would
indicate whether more widely available TSH-free
matrices in either freeze-dried or frozen form would be
suitable for use as common assay matices.
Participants
Nine laboratories participated in the study, and for
convenience in analysis have been referred to by a code
number from to 9, which does not relate to the order of
listing below. Each of the participants was a manufac-
turer of immunometric TSH immunoassay kits. Partici-
pants contributing data were:
Dr A. Swift, Diagnostic Products, 31 Station Lane,
Witney, Oxon OX8 6AN, UK.
Dr R. Palmer, Serono Diagnostics Ltd, Woking
Business Park, Woking, Surrey GU21 5JY, UK.
Dr S. R. Abbott, Boots-Celltech Diagnostics Ltd, 240
Bath Road, Slough, Berkshire SL1 4ET, UK.
Dr Gard Schnorr, Hoechst AG, Radiochemisches
Laboratorium, Postfach 80 03 20, D6230 Frankfurt/
Main 80, Germany.
Dr A. Massaglia, Diagnostics Division, Sorin Bio-
medica SpA, Str. per Crescentino 13040, Saluggia
(VC), Italy.
Dr H. Brettschneider, Boehringer Mannheim GmbH,
Abt. D-DQ, D8122 Penzberg, Nonnenwald,
Germany.
Drs Rudolf Nothelfer and Schuster, Henning Berlin
GmbH, Abt. Diagnostika, Komturstr. 58-62, D1000
Berlin 42, Germany.
Dr K. Pettersson, Wallac-Pharmacia P.O. Box 10, SF-
20101 Turku 10, Finland.
Mr J. Harris, Amerlite Quality Control, Amersham
International plc, Forest Farm, Whitchurch, Cardiff
CF4 7YT, UK.
Samples provided to participants
A summary of the sample together with their description
and the ’code name’ used for analysis and throughout this
report is given in table 1.
Assays requested
Each participant was requested to carry out three assays,
each including all samples listed above with at least
duplicate determinations for each sample.
Participants were also requested to include their in-house
calibrators made up in the routine manner, code named
’KIT’ for the analysis.
Reporting of data
All raw data, preferably as counts, extinction values, etc.,
were returned on centrally distributed data forms
together with details of the assays.R. E. Gaines-Das et al. Common matrix for TSH assays
Table 1. Coding ofsamples provided to participants.
Code used for
analysis and report Description of sample Comments
Centrally prepared calibrator sets
TTA Calibrator sets independently
TTB I
prepared in thyrotoxic serum
T3A Calibrator sets independently
T3B prepared in T3-suppressed serum
WGA Calibrator set prepared in
wheat-germ treated serum
Calibrator sets prepared in-house
T3F Calibrator set prepared in frozen
T3-suppressed serum
T3Y Calibrator set prepared from
lyophilized T3-suppressed serum
WGX Calibrator set prepared from
lyophilized wheat-germ
lectin-treated serum
KIT calibrators KIT
Samples
ERI-5
N1-4
N1D, N3D
O1, 02
Hyperthyroid samples
Normal (Euthyroid) samples
Duplicates of N1 and N3
Hypothyroid samples
Each calibrator set
contained TSH
concentrations of
0, 0"11, 0"34, 1"03
3"08, 10.3, 30"8
mU/L
Each calibrator set
contained TSH
concentrations of
0, 0"11, 0"33,
1, 3, 10 and 30 mU/L
Centrally prepared calibrator sets and samples were provided as 0"5 ml frozen aliquots with the only identification being a number
between and 55. The matrices for in-house calibrator sets (T3F, T3Y and WGX) were identified to participants as T3-suppressed
serum, Y and X respectively. Preparation ofin-house calibration was according to a provided protocol. Assay layout was randomised
according to a centrally-designed format. Both centrally-prepared and in-house calibrator sets were prepared using the ampoules TSH
preparation 81/565 [1].
Methods of statistical analysis
The analysis consisted of several stages. Initially, the
reported raw responses were examined for response error
relationships and for any notable outliers both graphi-
cally using plots of variance of responses against mean
responses, and statistically, using the program SCAN [2].
A maximum likelihood method was used for fitting the
parameter k of a response error relationship of the form
variance ofy proportional to yk [3]. Also at this stage raw
responses for the duplicated frozen samples (code names
N1 and N1D, T3P and T3PD, N3 and N3D) were
compared using analysis of variance within results for
each laboratory to detect any significant monotonic drift
in response data, and raw responses for the ’blanks’ with
presumed nil concentraion of TSH, namely the ’zero
dose’ concentrations for each calibrator set and the
hyperthroid patient samples, were analysed and
compared.
Secondly, common asymptotes based on four parameter
logistic curves were determined for each assay and used to
transform the raw responses to logits. Weighted linear
regresssion was then used to fit log dose-logit response
lines for each calibrator (code names KIT, TTA, TTB,
T3A, T3B, WGA, T3F, WGX and T3Y) [4]. The
resulting lines were examined, both graphically and
statistically, for linearity and parallelism within assays.
The within-assay ranks of the slopes of these lines were
compared across assays within laboratories for any
consistency of ordering.
The ’potencies’ ofthese various calibrators relative to one
another were calculated using the WRANL programme
for the analysis of parallel line assays [5], and compared
within and between laboratories using analysis of vari-
ance of logarithms of potency.
Finally, estimates of the TSH concentration for each of
the patient samples were made in terms of the various
calibrators, and within and between laboratory variances
for the logarithms of the potencies were computed and
compared.
Results and discussion
As described in materials and methods, the study has
been designed in order to analyse separately the factors
contributing to assay variation, in order to determine any
improvement that might be made by the use ofa common
assay matrix. The various levels of assay variation are
summarized in figure 1.
Analysis of intra assay monotonic ’drift’
Analysis ofcoded duplicate samples (N1, N1D, N3, N3D)
did not reveal any evidence ofintra-assay drift or random
errors, which would contribute significantly to within-
laboratory and between-laboratory variability (data not
shown).
Analysis of within-laboratory, between-assay variation
Each laboratory presented data from three separate
assays. Comparisons of the three assays therefore give an
estimate of within-laboratory, between-assay variation
for each participant. In general, estimates for relative
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Derived estimates
Estimates of replicate
samples within one assay
Individual assay estimates
calculated from sample
means
Laboratory means calculated
from individual assay
estimates
Oveall study means
calculated as geometric
means of laboratory means
Examples in this study
ID
A1 A2 A3
L1 L2 L9
GMPE
(geometric mean potency estimate)
Type of variation
Within-assay variation,
consisting of two
Randrh rmr rnnmnie
(pip,trine,
tc)
Within-laboratory,
between-assay variation
Between-laboratory variation
(overall coefficient of variation),
derived from two sources
between- between-
laboratory procedure
variation variation
potency of calibrator sets, ’zero’ TSH calibrators and
patient samples were consistent between assays, and
since within-laboratory between-assay variation did not
differ markedly among participants subsequent analyses
of the study are presented as overall geometric means of
all laboratory means, with the variance being expressed
as the geometric coefficient ofvariation, determined from
the standard deviation (SD) of the logarithms of labora-
tory means as (100 x (antilog(SD) -1)).
Analysis of assay matrix effects
Each assay contributed to this study included TSH
calibrator curves prepared in nine different matrices as
described in table 1. One of the matrices, that for the in-
house calibrator set (KIT in tables 2 and 3 and figure 2)
was individual to each participant calibrator; sets TTA,
TTB, T3A, T3B and WGA used common matrices with
centrally-prepared dilutions; and sets T3F, T3Y, WGX
used common matrices with dilutions prepared in-house.
Thus the data provided information on:
(1) The ’zero’ value for each matrix.
(2) The relative potencies of calibrator sets made up in
each common matrix compared to individual kit
calibrators.
(3) The estimates of TSH content for patient samples
using calibrator sets in each common matrix com-
pared to those using a kit calibrator.
(4) Between-laboratory variability for estimates in terms
of each calibrator, with some resolution of any
improvement in that variability into components due
to the use of centrally prepared dilutions, and to the
use of a common assay matrix.
’Zero’ levels in low TSH matrices
The ’zero’ response for each of the nine matrices in the
study was always lower than the lowest TSH dose (0" 11
mUlL) in the same matrix. The different laboratories
recorded different responses for the nine ’zero’ doses.
However, the only trend that was consistent and
significant was that the ’zero’ response on the WGA and
WGX calibrators tended to be highest (eight out of nine
laboratories) and in five out of nine laboratories was
higher than the responses given by the 0" 11 mUlL dose of
TSH in calibrator sets in the other seven matrices. These
data indicate that based on the ’zero’ response criterion,
matrices WGA and WGX are unsatisfactory, whilst the
other seven matrices give adequately low zero responses
(results not shown).
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Table 2. Overall geometric mean potency estimates and geometric coefficients of variation for various calibrators relative to selected
calibrators.
Reference calibrator
(potency 1’0)
Geometric mean potency estimates and geometric mean CV, (%)
for various calibrators relative to reference calibrator
T3A T3B T3F T3Y TTA TTB WGA WGX
KIT 1" 10 1" 11 1"07 1"06 1"05 1"02 1" 15 1’ 11
(21’) (19) (28) (26) (24) (21) (81) (91)
TTA 1.06 1.07 1.04 1.02 0.98 1.11 1.06
(10) (13) (15) (15) (5) (62) (71)
T3A 1.01 0.96 0.95 0.94 0.92 1.05 0.99
(7) (6) (8) (10) (12) (65) (73)
T3Y 1.05 1.07 1.01 0.98 0.97 1.08 1.04
(8) (12) (7) (15) (15) (70) (72)
WGX 1.01 1.03 0.97 0.96 0.94 0.93 1.04
(73) (82) (69) (72) (71) (79) (10)
Each assay contributed to the study included 9 TSH dose-response curves, for the calibrator sets described in table 1. The potency of
each of these calibrator curves was. estimated relative to that of a selected calibrator set. Laboratory means were pooled to give an
overall geometric mean potency estimate relative to that of the reference calibrator. The geometric mean coefficient of variation (in
parenthesis) is detemined from the standard deviation of the logarithms (in parenthesis) as 100x (antilog [SD]-I).
Table 3. Overall geometric mean potency estimates (mU/ml) and geometric CVfor patient samples estimates using selected calibrators.
Hyperthyroid samples Euthyroid and hypothyroid samples
Selected mU/L mU/L
calibrator (c.v. (%)) (c.v. (%))
ER1 ER2 ER3 ER4 ER5 NI NID N3 N3D N2 N4 O 02
KIT 0.05 0.02 0.10 0.03 0.05 1.15 1.12 3.40 3.36 2.05 0.35 16.4 5.04
(80) (131) (66) (21) (33) (25) (28) (21) (21) (29) (48) (38) (23)
TTA 0.05 0.02 0.10 0.03 0.05 1.10 1.08 3.26 3.24 1.96 0.34 15.7 4.85
(63) (120) (55) (33) (23) (15) (18) (19) (18) (18) (46) (35) (18)
T3Y 0.05 0.02 0.11 0.03 0.05 1.04 1.00 3.14 3.12 1.85 0.33 15.3 4.70
(62) (117) (62) (31) (18) (16) (15) (19) (23) (26) (58) (39) (21)
WGX 0.05 0.02 0.10 0.03 0.05 1.00 0.98 3.03 3.00 1.79 0.32 14.8 4.52
(74) (111) (104) (86) (79) (62) (56) (77) (74) (53) (162) (91) (73)
Laboratory means for the TSH content of each of the patient samples were pooled to overall geometric mean potency estimates
(mU/L). The geometric mean coefficient of variation (in parentheses) was calculated as described in table 2.
Relative potencies or calibrator sets
Each assay in each laboratory in the study included nine
different TSH dose response curves corresponding to
calibrator sets in the various matrices. By comparing one
selected dose-response curve with the other eight, a set of
relative potencies for the other various calibrator sets may
be obtained which would reveal any effects of the assay
matrix on the apparent potency in the various assays. In
table 2, five selected calibrators are used as the reference.
Generally, potency estimates performed in this way were
close to 1"0. Only five out of 36 estimates in table 2
differed by 10% or more from the reference calibrator,
with 15% being the greatest difference. These data
indicate therefore, that across the whole study there was
no significant effect of any matrix on the potency of the
calibrator set.
It was notable, however, that the WGX or WGA
calibrators, when compared with the others, gave con-
siderably higher geometric mean coefficients of variation
indicating that with these matrices some laboratories did
obtain more divergent results. Comparisons of estimates
in terms ofT3A and T3Y did not reveal any improvement
in overall between-laboratory variation as a result of the
use of centrally prepared dilutions rather than in-house
dilutions.
Patient sample estimates using the various calibrators
Overall geometric mean estimates for the 13 patient
samples, obtained using KIT, TTA, T3Y or WGX
calibrators are shown in table 3, and graphically in figure
2. The overall mean estimate for each sample was
consistent regardless of which calibrator set was used.
Overall coefficient of variation for patient samples using different
calibrator sets
The overall coefficients of variation for each patient
sample, calculated from calibrator sets in KIT, TTA,
T3Y gnd WGX are shown in table 3 and, graphically, in
figure 1. The following conclusion may be drawn.
(1) Estimates using calibrator WGX yielded signifi-
cantly higher variability than the other calibrators,
due to the anomalous results that this matrix
produced in some laboratories.
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Figure 2. Relationship between overall coefficient ofvariation and TSH contentforpatient samples. Overall geometric meanpotency estimates
and geometric mean coefficients of variation were calculated as described in table 3.
(2) The use ofcalibrators TTA and T3X gave a marginal
improvement in overall coefficient of variation for
most samples when compared to KIT calibrator.
(3) With the hyperthyroid samples, the factor deter-
mining the overall variation in estimates seems to be
’sample’ specific, rather than ’matrix’ specific. Thus
for samples ER3 (overall estimate 0" mU/L) and
ER1 (0"05 mU/L) the overall CVs were higher than
for ER5 (0"05 mU/L) or ER4 (0"03 mU/L). These
data indicate that individual assay systems may be
able to discriminate qualitatively different samples,
but that his discrimination would not be affected by
the use of a common matrix.
Conclusions
Two of the matrices tested (thyrotoxic serum pool or T3-
treated serum pool) were suitable for use as a common
matrix for TSH standards based on comparisons of
potency estimates, or of overall variability, and this
suitability was not affected by presentation (for example
lyophilized or frozen, and centrally prepared or in-house
dilutions using lyophilized matrix). The third matrix
(wheat-germ lectin treated serum) was not suitable in all
assay systems, emphasizing that matrix effects can occur
with unsuitable matrices. It remains possible that the
poor performance of the wheat germ lectin treated serum
was caused by its presentation in lyophilized form. This
seems unlikely however since the T3-suppressed serum
was not similarly affected by lyophilization.
The use of a common matrix only marginally improved
between-laboratory variability. This improvement is not
sufficient to justify the establishment and provision of a
centrally available common matix.
Variability of estimates for hyperthyroid samples may be
associated with intrinsic properties ofthe sample, causing
different reactions with different assay systems and is not
improved by the use of a common matrix.
The good agreement between in-house standards and the
centrally prepared calibrator sets reflects the high quality
of the kits tested.
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